[Misoprostol and induction of labour]

Area of Science:

• Obstetrics and Gynecology
• Pharmacology

Background:

• Misoprostol, a synthetic prostaglandin E1 (PGE1) analogue, shows promise for labor induction due to its low cost and high efficacy.
• Despite interest, Misoprostol is not yet a registered medication for routine obstetric practice.

Purpose of the Study:

• To compare the efficacy and safety of oral Misoprostol versus intravenous Oxytocin for labor induction.
• To evaluate the time interval from induction to delivery and the incidence of complications.

Main Methods:

• A study involving 47 patients undergoing labor induction, divided into two groups: Misoprostol (n=25) and Oxytocin (n=22).
• Misoprostol group received 50 mcg orally every 2 hours; the Oxytocin group received a standard infusion of 5 IU.
• Bishop Score and non-stress test (NST) were assessed before induction.

Main Results:

• The Misoprostol group experienced a significantly shorter induction-to-delivery interval (median 479 minutes) compared to the Oxytocin group (median 727 minutes).
• Uterine tachysystole occurred more frequently in the Misoprostol group (8%) than in the Oxytocin group (4.54%).
• 76% of patients receiving Misoprostol delivered within 24 hours.

Conclusions:

• Oral Misoprostol is an effective agent for inducing labor, particularly in patients with a low Bishop Score.
• No significant differences were observed in fetal distress monitoring, Apgar scores, or delivery methods between the groups.
• Further research is required to establish optimal dosing regimens and safety profiles to mitigate potential complications associated with incorrect Misoprostol administration.